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Abstract: Introduction: Psychotropic medication use is
associated with weight gain. While there are studies and
reviews comparing weight gain for psychotropics within
some classes, clinicians frequently use drugs from
different classes to treat psychiatric disorders.
Objective: To undertake a systematic review of all classes
of psychotropics to provide an all encompassing evi-
dence-based tool that would allow clinicians to determine
the risks of weight gain in making both intra-class and
interclass choices of psychotropics.
Methodology and Results: We developed a novel
hierarchical search strategy that made use of systematic
reviews that were already available. When such evidence
was not available we went on to evaluate randomly
controlled trials, followed by cohort and other clinical
trials, narrative reviews, and, where necessary, clinical
opinion and anecdotal evidence. The data from the
publication with the highest level of evidence based on
our hierarchical classification was presented. Recommen-
dations from an expert panel supplemented the evidence
used to rank these drugs within their respective classes.
Approximately 9500 articles were identified in our
literature search of which 666 citations were retrieved.
We were able to rank most of the psychotropics based on
the available evidence and recommendations from
subject matter experts. There were few discrepancies
between published evidence and the expert panel in
ranking these drugs.
Conclusion: Potential for weight gain is an important
consideration in choice of any psychotropic. This tool will
help clinicians select psychotropics on a case-by-case
basis in order to minimize the impact of weight gain when
making both intra-class and interclass choices.
Introduction
Weight Gain is associated with psychotropic medication use,
and while particular attention has been paid to atypical
antipsychotics, the typical antipsychotics, mood stabilizers, tricyclic
antidepressants (TCA’s), certain serotonin selective reuptake
inhibitors (SSRIs), and serotonin norepinephrine reuptake inhib-
itors (SNRIs) can cause weight gain as well. Because weight gain
and obesity are often overlooked in patients [1], there can be a
lack of follow-up to monitor for weight gain [2–7] or subsequent
weight related co-morbidities [8].
Psychotropic-induced weight gain is an important cause of non-
adherence to pharmacotherapy for antidepressant medications
[9–14], for antipsychotic medications [15–22] and for lithium
[23,24] and has been cited by an expert consensus panel on
adherence problems in serious and persistent mental illness
[25,26]. Non-adherence to prescribed medications places patients
at a greatly increased risk of illness exacerbation and re-
hospitalization. These costs are high [27], and were estimated to
range from $1392 million to $1826 million in 2005 in the US for
antipsychotics alone [28]. These issues are balanced by the
therapeutic benefit of the psychiatric medication. The CATIE trial
concluded that the superior efficacy of olanzapine might prevent
discontinuation due to weight gain [29,30]. This may suggest the
potential for weight gain may be offset by effectiveness or lack of
other adverse events.
Psychotropic-associated weight gain carries significant risk. As a
consequence, the weight-related co-morbidities associated with
these medications have been the most studied and we now have a
plethora of evidence on glucose dysregulation [29,31–41],
increases in triglycerides [29,41] and total cholesterol [29,42]
and hypertension. Fontaine [43] estimated that weight gain
associated with this class of drugs contributed to an increase in
mortality that offset the decreased risk of suicide with their use.
The adverse effects of long term weight gain have not escaped
regulatory bodies. A number of clinical practice guidelines
[4,44,45] and other studies [46–50] all recommend choosing
psychotropics least likely to cause weight gain, or switching to
those less likely to cause weight gain [51–53] if weight gain occurs.
This is because the CATIE trial data does provide some evidence
that patients who stayed on medications with high propensity to
induce weight gain, showed greater weight gain than those who
switched from these medications to other drugs that were less likely
to cause weight gain [54].
There are studies and reviews comparing weight gain for
psychotropics within classes for the atypical antipsychotics [29],
typical antipsychotics [36] and antidepressants [55]. But clinicians
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psychiatric disorder. Therefore, we saw a need for an all
encompassing evidence-based tool that would allow clinicians to
balance efficacy against the risks of weight gain in making both
intra-class and interclass choices of psychotropics [45,56–59].
Our primary objective was to consider weight change with
psychotropic drugs in adults with psychiatric conditions comparing
drugs to placebos or other psychotropics, more specifically, to
answer the following questions:
1. Is a particular psychotropic weight-neutral or is it associated
with weight gain or weight loss?
2. Can the weight gain be quantified?
3. What is the difference between the weight gain in drug-naı ¨ve
patients and the weight gain in those already on psychotropics?
4. How does the psychotropic rank with respect to weight gain in
its class?
Our secondary objective was to develop a clinical tool that
would provide information on psychotropic-associated weight gain
to allow clinicians to make informed choices with respect to this
important side effect.
Methods
While a Cochrane-style review is well suited for finding the
weight gain potential of a single drug or even a class of
psychotropics it becomes very cumbersome when seeking evidence
for all classes of psychotropics. We therefore developed a
hierarchical search strategy (Table 1) that made use of systematic
reviews that were already available. When such evidence was not
available we went on to evaluate clinical trials that were double
blind and randomly controlled, followed by cohort and other
clinical trials.
Inclusion Criteria
Studies were included if they contained information about
psychotropic drug use in patients with a psychiatric disease
(anxiety disorder, depressive illness, psychosis) or related condition
(chronic pain, fibromyalgia, chronic fatigue). The psychotropic
medication must have been compared with a placebo or
comparator drug, ideally for 12 or more weeks and reviews had
to report on weight change.
Exclusion Criteria
We excluded children (since normal growth would be a
confounder to evaluating weight gain) and patients with ADHD
(since many of the studies were done in children). We also
excluded subpopulations that may not be able to express drug-
induced weight gain, such as the elderly with dementia, those in
controlled environments where they may not have free access to
food, those with anorexia nervosa, bulimia nervosa, malignancies
and HIV disease. Studies were also excluded where the study drug
was added to multiple other psychotropics.
The Literature Search
A medical librarian searched a number of databases (from their
inception to April 2011) for articles where weight gain was
designated as the outcome or key word (Ovid Medline search
strategy Appendix S1, PsycINFO search strategy Appendix S2,
CCTR, CDSR (coch), Dare Search Strategy Appendix S3,
Embase search strategy Appendix S4.) These data bases were
then searched again, using the same search strategy and key words
for systematic reviews where weight gain was not a key word or
designated outcome. The searches were limited to English only
[60].
The literature search yielded almost 9500 reports. Two of four
potential reviewers (RD, AB, JP, GK) screened the reports for
eligibility according to the criteria in Table 1: on the basis of title,
then abstract, and then full-text reviews. At the title review stage,
Table 1. The Hierarchical strategy for selection of reports.
Level of study Description Rules for selection
I Systematic Review where weight
change is the focus or a key word
Rate according to Amstar [97]; The minimum criteria for a systematic review would be a search in 2
electronic databases using a stated search strategy; Where such reviews exist, choose in descending
order: the one with the highest rating and the most recent; If after 2 years of the chosen review, there is a
study in category III, then it is reviewed to determine if it changes the outcome; If there are two reviews at
level 1 or 2 of the same year, the one with the higher rating is chosen; If a systematic review contained
only one randomized controlled trial (RCT) dealing with weight then it is accepted as a systematic review
because it was felt that the process yielding negative results was important.
II Systematic Review where weight change
is not the focus but ‘‘side effects’’ or ‘‘
adverse events’’ or ‘‘tolerability’’ are
present in the key words or abstract.
Similar to above
III RCTs where weight change is a key
word
Duration .12 wks, n .50; Rate with SIGN 50 [98]; Where such studies exist as the highest level of
evidence, choose the one with the highest methodological rating and the most recent and no other
study; Where there is more than one RCT and there is disagreement, then chose the one with the highest
rating and acknowledge that there is disagreement
IV Cross-sectional or population studies
where weight change is a key word
Duration .12 wks, n .50; Rate with SIGN 50 [98]; Where such studies exist as the highest level of
evidence, choose in descending order, the one with the highest methodology rating according to SIGN
50 [98] and the most recent.
V Narrative Review with weight change is
a key word
Not graded; Only used if no other in levels I-IV available; If a narrative review contained only one RCT
dealing with weight then that RCT would be put in category 4 and take precedence over the narrative
review.
VI Other evidence/clinical experience or
studies that would be IV, or V where
the n,50 or duration ,12 wks
Not graded; Only used if no other in levels I-V available.
doi:10.1371/journal.pone.0036889.t001
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Assessment of Articles
Each study was given a number from I to VI based on the
hierarchical classification of the study according to the pre-
established criteria in Table 1. We used the AMSTAR scale, a
reliable and valid 11-item checklist for evaluating systemic reviews
to assess the methodological quality of the reviews chosen [61] and
graded according to good (A), fair (B), and poor (C). The quality of
each randomized controlled trial, cross-sectional or population
study was assessed using the SIGN 50 assessment form and
similarly graded [62]. The quality of evidence for change in weight
for a particular drug in a trial was graded with a score of 1, 2, or 3
according to quality. Each study was scored independently by two
out of four potential reviewers (AB, JP, RH, GK) and disagree-
ments were resolved by consensus. The individual that did the
scoring was never the same individual that did the initial reviewing
of that article.
Data Extraction and Building of a Database
For each article that met inclusion/exclusion criteria, quanti-
tative data (actual weight gain in drug-naı ¨ve and non drug-naı ¨ve
patients) of the study drug and its comparators was sought
wherever possible. If there was no quantitative evidence, the study
with the best qualitative evidence was obtained, whether or not the
drug was associated with weight gain. The sources of funding,
either direct (funding from a pharmaceutical manufacturer),
indirect (where authors had research funds) or unknown/
unfunded, psychiatric disease and the duration of study were also
extracted. Three groups of studies were collected: those giving
qualitative or quantitative information on a drug, those comparing
drugs within a class and those reporting weight gain in drug-naı ¨ve
patients.
Ranking of Psychotropics that Reported Weight Gain
In order to rank the weight gain caused by psychotropics, we
selected studies that dealt with multiple drugs. Because we were
not aware of any study that included all psychotropic drugs within
their respective class, we included all of the studies that qualified.
The data on ranking was extracted from each article and placed in
a separate table to allow a comparison of the change in weight
caused by psychotropics.
The Subject Matter Expert Panel
An expert panel was formed to review the rankings and to deal
with any potential discrepancies between articles. The methodol-
ogy for review and the membership were formulated by an
epidemiologist (G.W.). This panel consisted of 6 members: 4
psychiatrists (C.M., G.K., V.T.,R.H.); 1 family physician (S.W.),
whose practice was large and busy enough to include a large
number of patients with psychiatric illnesses and 1 internist (J.S.).
Secretarial assistance was provided by A.G. and R.D.
The mandate of this panel was to review the literature that was
used in developing the ranking of the psychotropics and to provide
comments on the rankings based on their clinical experience.
When there was a disagreement in the rankings, or when the
rankings were at variance from the clinicians’ experience, the
panel was asked to re-examine the articles in detail and attempt to
provide a rationale for the controversy. All controversies were
noted, as was the corresponding rationale.
Classification of Psychotropics and Presentation of Data
The recommendations from the panel were subsequently used
to rank the drugs within their respective classes. We have used a
common and largely mechanistic classification for the psychotro-
pics [63]. There does not seem to be a standardized classification –
often the term ‘‘second generation antipsychotics’’ is used rather
than ‘‘atypical antipsychotics’’ [45]. Given the results of the review
and the input of the expert panel, a table of weight analysis was
constructed.
Results
The screening for eligibility began by examining 3975 articles
(Figure S1). They included systemic reviews, randomized con-
trolled studies, cross-sectional or population studies, and narrative
reviews where weight gain was the focus. Of these, 956 articles
were requested for full text review. The second search of systemic
reviews, where weight gain was not a key word or identified in the
abstract, screened an additional 5500 articles. Of these, 957 were
requested for full text review. A short list of 666 articles resulted.
The older classes of psychotropics yield very little information
on weight gain. Ideally, the best ranking evidence for psychotro-
pics would come from drug-naı ¨ve patients, but there was no
ranking data available. We were only able to find data in drug-
naı ¨ve patients for 7 antipsychotics olanzapine, chlorpromazine,
clozapine, quetiapine, risperidone, aripiprazole and haloperidol.
There were 14 articles that met our hierarchical search strategy to
enable us to rank psychotropics. Two articles [60,61] ranked the
MAOIs (Table 2). Seven articles ranked the typical and atypical
antipsychotics (Table 3). Five articles were classified as level I,
three with good quality of evidence [62–64] and two provided
evidence that was fair. Two articles were level III with good
quality of evidence [29,65].
Six articles ranked the antidepressants (excluding MAOIs)
(Table 4). Three articles were classified as level I with quality of
evidence that was fair [66–68]. The most comprehensive ranking
data came from one article [55]. The ranking was based on the
data from drug non naı ¨ve patients. This article presented the effect
of each antidepressant on weight during two treatment periods, 4–
Table 2. MAOI ranking (ranked from most to least weight gain).
MAOI Author
Study
Level
Quality of Evidence
for the Drug
Funding
Source Effect on Weight
Phenelzine Garland [64] V 3 U Qualitative weight gain only.
Isocarboxazid Cantu [65] V 3 U Qualitative weight gain only
Tranylcypromine Garland [64] V 3 U Significant weight gain not noted when
compared with phenelzine
U = unfunded or unknown funding.
doi:10.1371/journal.pone.0036889.t002
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used to rank the antidepressants only when data from the longer
time period was not available. The quality of the evidence for the
change in weight was classified as good for the $4 month
treatment period interval. However, when the duration of the
treatment period was #12 weeks we assigned a poor quality rating
to the evidence. One article was classified as level III with evidence
that was fair [69] and the other article was level V with poor
quality of evidence [60].
Controversies in the ranking were reviewed by the expert panel
and they provided their recommendations which were incorpo-
rated into the above table. Three articles [55,67,68] provided
controversy in the ranking between paroxetine and mirtazapine.
Two articles [68] and [67] both concluded that mirtazapine
caused more weight gain that paroxetine. After reviewing the
evidence from the three studies, the ranking from the Serretti
article was selected due to the fact that the other two studies were
ranked lower on our scoring system, and were of shorter duration
compared to Serretti. It was also noted that the short term data
from these two articles were consistent with the short term data
from Serretti. In addition, although [68] and [67] were published
as two separate articles, they both obtained their data from the
same references.
There was agreement with the ranking of the tricyclic
antidepressants based on the Serretti article except for the ranking
of imipramine. Based on the clinical experience of the panel, all
tricyclic antidepressants are associated with some degree of weight
gain. One article [60] used to rank the antidepressants provided
evidence to support the claim that imipramine causes weight gain
in the long term. As a result, imipramine was ranked with, but
below, the other tricyclic antidepressants.
The data from Serretti on venlafaxine was #12 weeks. Based on
the clinical experience of the panel and the lack of long term data
on venlafaxine that met our selection criteria, the panel disagreed
with Serretti’s classification of venlafaxine as causing weight loss.
In their experience, longer term use of venlafaxine would not
result in significant weight loss and as a result it was ranked just
below escitalopram as venlafaxine was observed to have minimal
effect on weight in the long term.
The long term data on fluoxetine from the Serretti article would
imply that fluoxetine was associated with a small weight loss. The
panel considered fluoxetine as having minimal effect on weight.
Although there was no data to rank four antidepressants,
doxepin, trimipramine, fluvoxamine CR and desvenlafaxine, there
was quantitative and/or qualitative data available and this data
was included in the ranking table 4 [70–74].
There was no controversy between the two articles that ranked
the MAOIs [60,61]. In the panel’s opinion, the ranking in this
table was consistent with that seen in clinical practice.
Seven articles were located that met our criteria and provided
data to allow us to rank the typical and atypical antipsychotics
Table 3 [29,62–65,75,76]. The ranking was based on the data
from drug non naı ¨ve patients. There were a few discrepancies
identified that were presented to the panel for their recommen-
dations as five articles ranked both quetiapine and risperidone.
Two articles [75] and [29] ranked quetiapine as causing more
weight gain than risperidone, one article [76] provided qualitative
data only stating that they both caused weight gain, one article
[63] placed risperidone above quetiapine and one article [64]
concluded that they were similar. After reviewing the available
data the panel recommended placing quetiapine ahead of
risperidone acknowledging that at this time the literature indicates
the difference in weight gain between the two drugs is minimal.
One article [75] also stated that the weight gain caused by
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was presented on a scale of 1–5 without providing a range for their
scoring system.
We were also unable to find ranking data on drugs that were
available in formulations other than oral. For the drugs that are
available in formulations such as injectable that had quantitative
or qualitative data, we included this data in the ranking table with
the oral formulation. However the ranking of drugs in these tables
only applies only to the oral formulation.
Table 5 provides the weight gain caused by typical and atypical
antipsychotics and flunarizine but not ranked due to insufficient data.
Among the mood stabilizers, both lithium and valproate caused
weight gain (Table 6). Two studies were used to rank these two
drugs. The study presented by Melvin (Level II/B) [77] described
the weight gain due to both lithium and valproate as ‘‘++’’. The
Bowden study (Level III/B) [78] at 12 weeks ranks valproate
slightly ahead of lithium (1.1 kg vs 0.2 kg). Quantitative data
obtained from two different publications [79,80] and the clinical
impressions of the expert panel support the ranking of valproate
slightly ahead of lithium.
Anxiolytics
Qualifying papers were found for five benzodiazepines and
buspirone (Table 7). All of the anxiolytics were weight neutral.
Unfortunately, the highest level of evidence was III and all of the
data was qualitative only. There was no information for the
previous drug status of the patients included in these studies.
Discussion
In this review we used a predefined strategy to search for the
available evidence on the ability of psychotropics to induce
changes in body weight. The articles were selected based on a
hierarchical level of evidence and were subsequently evaluated
using AMSTAR for systematic reviews and SIGN 50 for
controlled trials. The best evidence available was presented. We
restricted our search to subjects with psychiatric disease since this
review is intended as a resource to help choose psychotropics for
psychiatric illness according to risk of weight gain.
Although most antipsychotics were found to be associated with
weight gain, there are inherent difficulties in quantifying this
weight. Many trials did not account for weight gain among the
reported side-effects, some reported change in mean body weight,
and some reported the percentage who gained more than 7% of
their initial body weight. Many studies did not consider drug
dosages or parameters for drug adherence, gender, and pharma-
cogenetics. Most studies had high dropout rates. There are factors
that would result in significant underestimations of weight gain
potential. These include studies of short duration, the use of last
observation carried forward to handle data from study dropouts,
previous drug use that would cause weight gain, and industry
sponsorship.
Since the treatment of psychiatric illness often takes months or
years, and because it takes time for weight gain to develop, we
selected articles with study duration of 12 weeks or longer.
Unfortunately, many of the randomized clinical trials were of short
duration and thus were not able to provide sufficient information
about the full impact of the drug on body weight. Kinon [81] and
Tran [82] reported on the time course of weight gain with
olanzapine; they showed continued weight gain up to 39 and 22
weeks.
Recovery from the psychiatric illness itself may influence study
outcome. This may be a more important factor in the treatment of
depression than of other psychiatric disorders [83]. Also, measures
that patients take to offset weight gain are rarely discussed but may
influence the degree to which a patient gains weight.
The effect of drug dosage on weight gain has been reviewed
[84], but it is rarely discussed in reviews. We minimized this effect
by verifying that all studies and reviews also had efficacy as an
outcome measure.
We found only two studies that addressed the issue of drug
adherence by determining plasma drug levels in the study subjects
[85,86]. Genetic and gender differences may also be significant
factors affecting a patient’s side-effect response to these drugs [87].
Pharmacogenetics approaches may offer the possibility of identi-
fying patient-specific biomarkers for predicting the risk of these
side effects [88]. A retrospective chart review [89] indicates that
women and those with a greater initial BMI are more susceptible
to weight gain [87], for example, obese patients given lithium
gained more weight on lithium compared with lean patients [79].
There were high drop-out rates in many of the studies. In one
study 74% of the patients discontinued the study medication
within 18 months. The Last Observation Carried Forward
(LOCF) method used in many studies for dealing with dropouts
is likely to underestimate drug-associated weight gain [90].
Many studies have confounding variables that have contributed
to the underestimation of drug-induced weight gain. Weight gain
differs between those with previous psychotropic treatments and
those previously unexposed to psychotropics. In patients who are
not drug-naı ¨ve, weight gain can be affected by the previous drug as
well as the study drug. For example, studying the weight gains with
long-acting risperidone in patients who had been switched from
other antipsychotics, Lindenmayer [91] found an overall mean
weight gainof 0.4 kg over 12 weeks. The same study found a gainof
1.4 kg in patients who had been on haloperidol and of 0.3 kg in
those who had been on quetiapine, and a loss of 0.5 kg in those on
olanzapine. This shows that absolute weight gain is underestimated
in studies that include patients who are not drug-naı ¨ve. Weight gain
was three to four times greater in studies that included individuals
with limited previous exposure to antipsychotic drugs [62].
Approximately one third of the studies presented in the tables
were directly funded by pharmaceutical manufacturers. This
number may be underestimated because many of the studies did
not declare their source of funding. Two systematic reviews,
Sismondo, and Ahmer conclude that pharmaceutical company
sponsorship is strongly associated with results that favour the
sponsors’ interests [92,93]. In studying ‘‘wish bias’’ in antidepres-
sant drug trials, Barbui found that fluoxetine was favoured in
clinical trials when fluoxetine was the experimental agent, and that
comparator antidepressants were favoured in trials using fluoxe-
tine as the reference agent [94]. In a report with a noteworthy title
(‘‘Why Olanzapine beats Risperidone, Risperidone beats Quetia-
pine and Quetiapine beats Olanzapine’’) Heres et al come to the
same conclusion and suggest ways in which potential sources of
bias can be addressed by study initiators, peer reviewers and
readers [95]. However, in a secondary analysis of a systematic
review, Gartelhner found that the effect of study sponsorship on a
systematically evaluated body of evidence of head-to-head trials
was modest and perhaps not clinically significant [96].
We saw an urgent need for a clinical tool to allow choice of
psychotropic drugs with respect to weight change. A full systematic
review was beyond the scope of our resources, we therefore
developed this hierarchical approach. The biggest challenge in
conducting this systematic synthesis was the analysis of very
heterogeneous study designs. While we have done our best to
summarize the extremely large amount of published literature, we
caution the user about the limitations of this analysis. These
limitations include drug dosage, variation in reporting of weight
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therapy vs. combination therapy, duration of treatment, psychi-
atric diagnosis, baseline patient characteristics such as age, gender,
BMI, genetic factors, recovery from the underlying condition and
concurrent weight treatments during the study.
The findings of this review highlight the need for the
development of psychotropics that are not associated with weight
gain. As well, a better understanding of the pharmacogenetics of
psychotropic drug response might help select psychotropics for
individuals so that weight gain is minimized. It is important to
consider methods for minimizing the impact of weight gain
induced by psychotropic drugs. Choices must be made on a case-
by-case basis, with careful consideration of issues of weight,
therapeutic efficacy, and other relevant factors discussed in this
paper in order to minimize the impact of weight gain with
psychotropic medications.
Further research is needed to determine actual weight gain for all
psychotropics in drug naı ¨ve patients for sufficient lengths of time to
determine the full impact of the weight gain and co-morbidities of
this weight gain. These studies should be done at arms-length from
industry funding and reported in both mean weight change and
percent who gain more than 7% of initial body weight.
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